TGX Theragenics Corp.

International Physician Networks dba International Urology Network and Theragenics Corporation Sign Exclusive Three-Year Strategic Alliance BALTIMORE, Nov. 10 /PRNewswire-FirstCall/ -- International Physician Networks dba International Urology Network (IUN) announced today that it has entered into a three-year exclusive, strategic, alliance agreement with Theragenics Corporation(R) (NYSE:TGX). This agreement will provide group purchasing services to over 3,500 of IUN's community-based urologists for Theragenics Corporation(R)'s palladium-103 device TheraSeed(R) and I-Seed, an iodine-125-based device. It also has the potential to expand the strategic relationship to include medical education programming to IUN's growing urology physician practice membership. "We are pleased to have the opportunity to work with Theragenics Corporation(R), a leading provider of brachytherapy treatment devices for prostate cancer. We look forward to helping them improve the health and quality of life for prostate cancer patients," said Anthony J. Corrao, Executive Vice President, Global Sales and Development of International Physician Networks. "Our community-based urology practices have expressed their interest in expanding their ancillary services and have specifically targeted brachytherapy as a preferred treatment option." "This new relationship with IUN presents several opportunities for Theragenics. IUN brings groups of physicians, specifically urologists in their position as gatekeepers, into an arena that could benefit brachytherapy as a whole," said Christine M. Jacobs, Chairman, CEO and President of Theragenics Corporation(R). "It is our hope this relationship provides a fresh channel for exposure of prostate cancer patients to brachytherapy. It also holds promise for those loyal radiation oncologists who recognize our treatment option for prostate cancer is the new gold standard. IUN is one of the first groups of its kind to identify this unique opportunity and we look forward to being a part of their success in this exciting endeavor." Theragenics Corporation(R) is committed to being a leading provider of brachytherapy treatment devices for prostate cancer and other degenerative disease states. The company is the manufacturer and marketer of the palladium-103 device TheraSeed(R) and I-Seed, an iodine-125-based device. Both devices are used in the treatment of localized prostate cancer in one-time, minimally invasive procedures. Theragenics(R) is the world's largest producer of palladium-103 and is involved in research and development utilizing palladium-103 and other isotopes for the treatment of a wide variety of diseases, including vascular disease and macular degeneration. For additional information on the company, call Theragenics' Investor Relations Department at (800) 998-8479. Additional information can be found on the company website: http://www.theragenics.com/. International Physician Networks is a subsidiary of AmerisourceBergen Corporation (NYSE:ABC), the world's leading pharmaceutical distributor. IPN is a diversified physician services organization specializing in the support of community-based practices. The company offers its members a variety of value-added services that enable practices to remain efficient, effective, and to continue to deliver quality patient care. DATASOURCE: International Physician Networks CONTACT: Erin Mulgrew of International Physician Networks, +1-410-385-2900 or Web site: http://www.theragenics.com/ Web site: http://www.ipnonline.com/

Copyright